JP2022500431A5 - - Google Patents
Info
- Publication number
- JP2022500431A5 JP2022500431A5 JP2021514070A JP2021514070A JP2022500431A5 JP 2022500431 A5 JP2022500431 A5 JP 2022500431A5 JP 2021514070 A JP2021514070 A JP 2021514070A JP 2021514070 A JP2021514070 A JP 2021514070A JP 2022500431 A5 JP2022500431 A5 JP 2022500431A5
- Authority
- JP
- Japan
- Prior art keywords
- etv1
- erg
- combination
- pharmaceutical compositions
- compositions according
- Prior art date
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730869P | 2018-09-13 | 2018-09-13 | |
| US62/730,869 | 2018-09-13 | ||
| US201862737612P | 2018-09-27 | 2018-09-27 | |
| US62/737,612 | 2018-09-27 | ||
| US201862778185P | 2018-12-11 | 2018-12-11 | |
| US62/778,185 | 2018-12-11 | ||
| PCT/US2019/050970 WO2020056232A1 (en) | 2018-09-13 | 2019-09-13 | Combination therapy for the treatment of prostate cancer |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022500431A JP2022500431A (ja) | 2022-01-04 |
| JPWO2020056232A5 JPWO2020056232A5 (https=) | 2022-09-22 |
| JP2022500431A5 true JP2022500431A5 (https=) | 2022-09-22 |
| JP7441214B2 JP7441214B2 (ja) | 2024-02-29 |
Family
ID=69778254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514070A Active JP7441214B2 (ja) | 2018-09-13 | 2019-09-13 | 前立腺がんの治療のための併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220117942A1 (https=) |
| EP (1) | EP3849544A4 (https=) |
| JP (1) | JP7441214B2 (https=) |
| KR (1) | KR102844523B1 (https=) |
| CN (1) | CN112912075B (https=) |
| AU (1) | AU2019338483B2 (https=) |
| CA (1) | CA3112396A1 (https=) |
| IL (1) | IL281281B2 (https=) |
| MX (1) | MX2021002884A (https=) |
| SG (1) | SG11202102492PA (https=) |
| TW (1) | TWI816880B (https=) |
| WO (1) | WO2020056232A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI882964B (zh) | 2018-09-13 | 2025-05-11 | 大陸商恒翼生物醫藥（上海）股份有限公司 | Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法 |
| US20220265618A1 (en) * | 2021-02-22 | 2022-08-25 | Celgene Quanticel Research, Inc. | Methods of treating prostate cancer |
| CN114644687B (zh) * | 2022-04-07 | 2023-06-27 | 华中科技大学同济医学院附属协和医院 | 一种可拮抗rbm25蛋白rna结合活性的多肽rbip-21及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| EP2621483A1 (en) * | 2010-09-27 | 2013-08-07 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| CA2915838C (en) * | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| WO2015065919A1 (en) * | 2013-10-28 | 2015-05-07 | The Regents Of The University Of California | Treatment of metastatic prostate cancer |
| NO2719005T3 (https=) * | 2014-07-28 | 2018-01-20 | ||
| WO2016171470A1 (en) * | 2015-04-21 | 2016-10-27 | Kainos Medicine, Inc. | Bromodomain-inhibiting compounds and methods to prevent or treat a cancer |
| WO2017216772A2 (en) * | 2016-06-16 | 2017-12-21 | The University Of Chicago | Methods and compositions for treating breast and prostate cancer |
| WO2018097977A1 (en) * | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Crystalline forms of a phosphate complex of a bet inhibitor |
| WO2018106433A1 (en) * | 2016-12-06 | 2018-06-14 | Gilead Sciences, Inc. | Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent |
-
2019
- 2019-09-12 TW TW108133128A patent/TWI816880B/zh active
- 2019-09-13 EP EP19860912.5A patent/EP3849544A4/en active Pending
- 2019-09-13 WO PCT/US2019/050970 patent/WO2020056232A1/en not_active Ceased
- 2019-09-13 JP JP2021514070A patent/JP7441214B2/ja active Active
- 2019-09-13 MX MX2021002884A patent/MX2021002884A/es unknown
- 2019-09-13 IL IL281281A patent/IL281281B2/en unknown
- 2019-09-13 AU AU2019338483A patent/AU2019338483B2/en active Active
- 2019-09-13 CA CA3112396A patent/CA3112396A1/en active Pending
- 2019-09-13 CN CN201980059904.2A patent/CN112912075B/zh active Active
- 2019-09-13 KR KR1020217010491A patent/KR102844523B1/ko active Active
- 2019-09-13 SG SG11202102492PA patent/SG11202102492PA/en unknown
- 2019-09-13 US US17/275,473 patent/US20220117942A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105873440B (zh) | 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途 | |
| JP2022500435A5 (https=) | ||
| WO2021262484A1 (en) | Combination therapy for treatment of cancer | |
| JPWO2020053655A5 (https=) | ||
| US20160287605A1 (en) | Combination therapy | |
| CN101686972A (zh) | 治疗用组合物和方法 | |
| AR094654A1 (es) | Modulador del receptor de andrógeno y sus usos, método para tratamiento, composición farmacéutica | |
| JP2022500431A5 (https=) | ||
| TWI873485B (zh) | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 | |
| JP2016528162A (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
| JP6768682B2 (ja) | メラノーマの処置に使用するためのアピリモド | |
| JP2020516646A5 (https=) | ||
| CA3080644A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| CN106573042A (zh) | 治疗多发性骨髓瘤的药物组合 | |
| JP2015517523A5 (https=) | ||
| JP2017507151A5 (https=) | ||
| JP2013538200A (ja) | 癌治療用の新規併用療法 | |
| AU2013254468A1 (en) | Dexanabinol or a derivative thereof for use in the treatment of cancer in dose ranges of 2-30 mg/kg | |
| JP2015214579A (ja) | 癌細胞アポトーシス | |
| JP2019513812A (ja) | 化学療法の改善 | |
| US9867865B1 (en) | Mesalamine for the treatment of cancer | |
| JP2021505669A5 (https=) | ||
| JP2019507786A5 (https=) | ||
| UA82071C2 (en) | Therapeutic use of n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide for treatment of cancer and pain caused by it | |
| TW202110448A (zh) | Ｐａｒｐ抑制劑聯合ｖｅｇｆｒ抑制劑用於治療卵巢癌或乳腺癌的用途 |